Skip to main content
. 2020 Dec 3;35(2):333–345. doi: 10.1038/s41375-020-01102-3

Fig. 3. Progression-free survival of WM patients treated with ibrutinib/rituximab versus placebo/rituximab.

Fig. 3

The iNNOVATE phase III randomized study (a) for the total patient group and (b) depending on the MYD88/CXCR4 mutational status [108].